Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEGFR1-A24-1084
- Development stage
- Phase 2
- Lead developer
- Institute of Medical Science University of Tokyo
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
VEGFR1-A24-1084 is a synthetic peptide vaccine designed to induce cytotoxic T lymphocyte (CTL) responses against cells expressing vascular endothelial growth factor receptor 1 (VEGFR1). The peptide is restricted to the HLA-A*2402 allele and targets tumor angiogenesis by stimulating an immune response specifically against tumor vascular endothelial cells. It has been investigated in phase I and II clinical trials for advanced solid tumors, including gastric cancer, glioma, and metastatic renal cell carcinoma. The primary mechanism of action is immunostimulation via induction of CTLs that recognize the VEGFR1 epitope presented on tumor vasculature. Clinical studies have shown that the vaccine can induce specific immune responses with a favorable safety profile when administered alone or in combination with chemotherapy[3][6][7][9].
- Other names
- VEGFR1 peptide vaccine (A24-restricted)HLA-A*2402-restricted VEGFR1 peptide vaccine
02
Targets
HLA-A*24 (Major histocompatibility complex class I molecule presenting MAGE-A4 peptide)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on VEGFR1-A24-1084.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VEGFR1-A24-1084.